FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384565015> ?p ?o ?g. }

• W4384565015 endingPage "112984" @default.
• W4384565015 startingPage "112984" @default.
• W4384565015 abstract "Background The French phase II AcSé-crizotinib trial aimed to evaluate the safety and efficacy of crizotinib in patients with ALK, ROS1 and MET-driven malignancies including ALK-positive, anaplastic large cell lymphoma (ALK+ALCL). Methods ALK+ALCL patients 12 months or older with measurable disease and no standard care options available received crizotinib twice daily at 165 mg/m2 in children and adolescents and 250 mg in adults. The primary endpoint was the response rate at 8 weeks. Results Twenty-eight patients were enrolled between 02/2014 and 03/2018. Three patients, not treated, were excluded from analysis. Median age was 19 years. Median previous line of chemotherapy was two. In the 24 patients with evaluable response, the response rate at 8 weeks was 67% (95%CI:47-82%). All patients discontinued crizotinib after a median treatment duration of 3.7 months: 8 for progression, 2 for adverse events related to prior treatments, and 15 by choice including 6 for allogenic stem-cell transplantation. The median follow-up was 45 months. Nine patients experienced an event: eight relapses (seven after crizotinib discontinuation and one after dose reduction) and one died in complete remission. The median duration of response was 43.3 months (95%CI:8.3-not reached). The 3-year-progression-free and overall survival rates were 40%(95%CI:23-59%) and 63%(95%CI:43-79). Grade 3 or 4 treatment-related adverse events occurred in 32% of patients. Conclusion Crizotinib shows efficacy and an acceptable safety profile in ALK+ALCL relapsed/refractory patients. However, a large proportion of patients experience a relapse after crizotinib discontinuation. Future studies will assess if prolonged ALK inhibitor exposure has curative potential without consolidation." @default.
• W4384565015 created "2023-07-18" @default.
• W4384565015 creator A5002010740 @default.
• W4384565015 creator A5002121884 @default.
• W4384565015 creator A5012706246 @default.
• W4384565015 creator A5017625077 @default.
• W4384565015 creator A5019565330 @default.
• W4384565015 creator A5023945751 @default.
• W4384565015 creator A5031216970 @default.
• W4384565015 creator A5034965143 @default.
• W4384565015 creator A5037596808 @default.
• W4384565015 creator A5041372516 @default.
• W4384565015 creator A5044218617 @default.
• W4384565015 creator A5044244437 @default.
• W4384565015 creator A5047227776 @default.
• W4384565015 creator A5051605599 @default.
• W4384565015 creator A5060930412 @default.
• W4384565015 creator A5067202962 @default.
• W4384565015 creator A5067410613 @default.
• W4384565015 creator A5067560032 @default.
• W4384565015 creator A5069345610 @default.
• W4384565015 creator A5077634240 @default.
• W4384565015 creator A5078156775 @default.
• W4384565015 creator A5079274311 @default.
• W4384565015 creator A5079749862 @default.
• W4384565015 creator A5081284539 @default.
• W4384565015 creator A5089493611 @default.
• W4384565015 creator A5089621837 @default.
• W4384565015 date "2023-09-01" @default.
• W4384565015 modified "2023-10-16" @default.
• W4384565015 title "Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial" @default.
• W4384565015 cites W1939376872 @default.
• W4384565015 cites W1993428519 @default.
• W4384565015 cites W2019108602 @default.
• W4384565015 cites W2119147717 @default.
• W4384565015 cites W2137585388 @default.
• W4384565015 cites W2147038864 @default.
• W4384565015 cites W2160516333 @default.
• W4384565015 cites W2309708317 @default.
• W4384565015 cites W2320580975 @default.
• W4384565015 cites W2561527502 @default.
• W4384565015 cites W2736812323 @default.
• W4384565015 cites W2742652175 @default.
• W4384565015 cites W2793539228 @default.
• W4384565015 cites W2796718775 @default.
• W4384565015 cites W2903308035 @default.
• W4384565015 cites W2938912331 @default.
• W4384565015 cites W2947111277 @default.
• W4384565015 cites W2948011872 @default.
• W4384565015 cites W3042967359 @default.
• W4384565015 cites W3046021472 @default.
• W4384565015 cites W3081214124 @default.
• W4384565015 cites W3090473304 @default.
• W4384565015 cites W3093539975 @default.
• W4384565015 cites W3134569209 @default.
• W4384565015 cites W3207500627 @default.
• W4384565015 cites W4226116613 @default.
• W4384565015 cites W4229367408 @default.
• W4384565015 cites W4280517527 @default.
• W4384565015 doi "https://doi.org/10.1016/j.ejca.2023.112984" @default.
• W4384565015 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37549532" @default.
• W4384565015 hasPublicationYear "2023" @default.
• W4384565015 type Work @default.
• W4384565015 citedByCount "0" @default.
• W4384565015 crossrefType "journal-article" @default.
• W4384565015 hasAuthorship W4384565015A5002010740 @default.
• W4384565015 hasAuthorship W4384565015A5002121884 @default.
• W4384565015 hasAuthorship W4384565015A5012706246 @default.
• W4384565015 hasAuthorship W4384565015A5017625077 @default.
• W4384565015 hasAuthorship W4384565015A5019565330 @default.
• W4384565015 hasAuthorship W4384565015A5023945751 @default.
• W4384565015 hasAuthorship W4384565015A5031216970 @default.
• W4384565015 hasAuthorship W4384565015A5034965143 @default.
• W4384565015 hasAuthorship W4384565015A5037596808 @default.
• W4384565015 hasAuthorship W4384565015A5041372516 @default.
• W4384565015 hasAuthorship W4384565015A5044218617 @default.
• W4384565015 hasAuthorship W4384565015A5044244437 @default.
• W4384565015 hasAuthorship W4384565015A5047227776 @default.
• W4384565015 hasAuthorship W4384565015A5051605599 @default.
• W4384565015 hasAuthorship W4384565015A5060930412 @default.
• W4384565015 hasAuthorship W4384565015A5067202962 @default.
• W4384565015 hasAuthorship W4384565015A5067410613 @default.
• W4384565015 hasAuthorship W4384565015A5067560032 @default.
• W4384565015 hasAuthorship W4384565015A5069345610 @default.
• W4384565015 hasAuthorship W4384565015A5077634240 @default.
• W4384565015 hasAuthorship W4384565015A5078156775 @default.
• W4384565015 hasAuthorship W4384565015A5079274311 @default.
• W4384565015 hasAuthorship W4384565015A5079749862 @default.
• W4384565015 hasAuthorship W4384565015A5081284539 @default.
• W4384565015 hasAuthorship W4384565015A5089493611 @default.
• W4384565015 hasAuthorship W4384565015A5089621837 @default.
• W4384565015 hasBestOaLocation W43845650151 @default.
• W4384565015 hasConcept C126322002 @default.
• W4384565015 hasConcept C141071460 @default.
• W4384565015 hasConcept C141341695 @default.
• W4384565015 hasConcept C143998085 @default.
• W4384565015 hasConcept C197934379 @default.
• W4384565015 hasConcept C203092338 @default.

• next